This HTML5 document contains 194 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n12http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q38393045
rdf:type
wikibase:Item
schema:description
2016年论文 bài báo khoa học научна статия 2016年論文 vetenskaplig artikel artigo científico tieteellinen artikkeli articol științific 2016年论文 научни чланак teaduslik artikkel სამეცნიერო სტატია scientific article published on 02 May 2016 מאמר מדעי artículo científico artikull shkencor мақолаи илмӣ artigo científico 2016년 논문 2016年論文 article scientifique vitenskapelig artikkel wissenschaftlicher Artikel article científic 2016年论文 2016年の論文 vitskapeleg artikkel article scientific 2016年论文 বৈজ্ঞানিক নিবন্ধ наукова стаття, опублікована в травні 2016 artikel ilmiah مقالة علمية نشرت في 02 مايو 2016 научная статья 2016年論文 2016 nî lūn-bûn artykuł naukowy vědecký článek artigo científico научни чланак scienca artikolo tudományos cikk 2016年論文 2016年论文 artículu científicu espublizáu en 2016 scientific article published on 02 May 2016 naučni članak artikulong pang-agham bilimsel makale articolo scientifico 2016年论文 επιστημονικό άρθρο vedecký článok 2016年論文 wetenschappelijk artikel บทความทางวิทยาศาสตร์ videnskabelig artikel scientific article published on 02 May 2016
p:P577
wds:Q38393045-1771C1D1-510D-4FEF-A392-E68079C4DE13
wdt:P577
2016-05-02T00:00:00Z
p:P407
wds:Q38393045-0562609F-D79B-4EC5-925C-5E7DD48555D9
wdt:P407
wd:Q1860
p:P2860
wds:Q38393045-F171A7CC-A262-4CB0-AE43-80A0B9BA9537 wds:Q38393045-F3ED4A26-6C0D-4DDC-91A8-5E25775D053C wds:Q38393045-F9B453E3-F2CF-432D-A0DE-B390173AE52C wds:Q38393045-CC87E263-CF47-40AC-8CB2-E0A89462477D wds:Q38393045-EB7EB0D3-1978-4DA6-8096-6DC5262FE83D wds:Q38393045-8CF33FE5-D3B9-44D7-B195-4E058C043D84 wds:Q38393045-9392CB0D-BF29-4D3C-A4FC-57BC7540F0D1 wds:Q38393045-88BBF96D-FA90-461E-9E88-8D2A09A770EE wds:Q38393045-8B66119E-DBB3-4FEE-9F33-FDC770ADD6C8 wds:Q38393045-8111618D-B9E4-455F-9751-2E3A9910E8AF wds:Q38393045-8131021C-0E44-4B3E-946B-7BA45E1898EF wds:Q38393045-82975F4A-D5E8-42C4-837B-102C49DF75C0 wds:Q38393045-6D8549E5-017A-4837-B87E-B8F9C4C8882E wds:Q38393045-7A7F3E37-FC7B-49DD-9383-20AC5891BFAC wds:Q38393045-7AFA944E-5121-4910-B47E-FBF0F1659FCA wds:Q38393045-7CDEC9AE-9B22-45E3-B06C-8A2590313B71 wds:Q38393045-C4ACD388-1C01-4047-B907-C872C3C958A3 wds:Q38393045-C8BC8E51-E17E-47FD-A7BC-64198AAFB6A2 wds:Q38393045-CAD283B8-8150-4098-95DA-D66F36C9EEF3 wds:Q38393045-C307A82E-60D0-4AB7-A4D3-BCB5AECDBC32 wds:Q38393045-AFEB78FB-E503-45F9-AFA2-CC0D3AA188BC wds:Q38393045-B08E9D76-932A-4BB0-A199-99A3D1FCDFCC wds:Q38393045-B4E49B5B-CB80-4E45-85E9-81A1FF6B5989 wds:Q38393045-9F33FFBD-CA36-45C2-9BDE-8F881615B0C2 wds:Q38393045-A5C9C987-1590-46BC-9E59-85FA740FB201 wds:Q38393045-A96F834F-50F2-48F4-AF45-8CD714E5CFEC wds:Q38393045-12FDE42B-7442-43E5-A610-6AC0AF73D9EF wds:Q38393045-1687A25C-8D28-4588-B521-539D9AC5147F wds:Q38393045-0AAADB09-C7F7-4D5A-9D3F-711C31C152D0 wds:Q38393045-468153D4-AF1B-449E-81B8-AB04212ADF90 wds:Q38393045-677D83E7-FE4D-4D5D-A3BB-E18811505E60 wds:Q38393045-4133935C-4BE3-4B16-9094-AD1CF4ECD695 wds:Q38393045-2E8EDEA5-6135-4533-80BF-3AABB1209585 wds:Q38393045-31AA954A-E7C9-479E-9429-51806E8382E9 wds:Q38393045-1FCADEA9-CAF4-4514-8013-0920A117F161 wds:Q38393045-2C5A8FDC-5F44-4EA6-81F1-5849A7A4244A
wdt:P2860
wd:Q34658655 wd:Q34733516 wd:Q37580439 wd:Q56904280 wd:Q34172008 wd:Q39605778 wd:Q46389190 wd:Q42510173 wd:Q24633070 wd:Q35052176 wd:Q36245546 wd:Q29391607 wd:Q42451354 wd:Q34996647 wd:Q30354522 wd:Q28131650 wd:Q29620881 wd:Q41035618 wd:Q35633680 wd:Q57660183 wd:Q37407985 wd:Q36145430 wd:Q61965252 wd:Q27860852 wd:Q42482998 wd:Q35870655 wd:Q39013804 wd:Q58211903 wd:Q29620851 wd:Q28243071 wd:Q29620814 wd:Q37724790 wd:Q24630844 wd:Q35692146 wd:Q37744341 wd:Q34454922
p:P2093
wds:Q38393045-FD5A40BF-584F-4740-AE68-E9B719D122A7 wds:Q38393045-4470B33E-C3A8-4376-B05E-62DC7876958E wds:Q38393045-36C3307C-1C54-4B49-A4B9-D36E3C9F143D wds:Q38393045-5A0B0C33-E902-4764-B1B8-CA77B942FA0F wds:Q38393045-24F68BE3-188A-41B0-B73A-450DE34C99E5 wds:Q38393045-30A66AE3-223D-4B1E-8F8E-0E3871093711 wds:Q38393045-0DBC041C-FF7D-4CA7-8B7C-90EDEED7D152 wds:Q38393045-C440BA19-9A2E-4E65-B11C-EC1D243BF27B wds:Q38393045-9E4F515D-1971-4BF7-8645-5952B1010ADD wds:Q38393045-865AFCE3-767D-47CF-8B1E-0A0EF949419E wds:Q38393045-853E6D6D-AEF4-483B-8BFD-0621BC8458CB
wdt:P2093
Gursel Aktan Lajos Pusztai Laura Q M Chow Rita Nanda Vassiliki Karantza Ravit Geva Laurence Buisseret Kumudu Pathiraja Shilpa Gupta Raanan Berger Jonathan D Cheng
rdfs:label
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
skos:prefLabel
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
schema:name
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
p:P50
wds:Q38393045-CF68E5A4-6943-4EF0-90D8-B958E8235E3A
wdt:P50
wd:Q109984365
p:P1476
wds:Q38393045-33B560F0-AE94-4403-97EF-95B318D99AB9
wdt:P1476
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
p:P304
wds:Q38393045-B265701A-36F2-46F7-9834-9EA485F372B3
wdt:P304
2460-2467
p:P31
wds:Q38393045-BEC27045-2DD9-4833-AF3E-CDCF63C7048B
wdt:P31
wd:Q13442814
p:P921
wds:Q38393045-94289C62-45EB-4FFC-8C61-08F2B7EF3106 wds:Q38393045-C327A8E8-75C3-4A1B-BEDE-A6F2E9909EE9 wds:Q38393045-D892470B-5BE9-4689-81E9-27E8434875C1
wdt:P921
wd:Q128581 wd:Q7843332 wd:Q13896859
p:P698
wds:Q38393045-952A3402-97FD-47E7-BE30-910EBCC22FDC
wdtn:P698
n8:27138582
wdt:P698
27138582
p:P1433
wds:Q38393045-50EC5EB5-CFF7-458C-90FB-14A4D44E88E1
wdt:P1433
wd:Q400292
p:P433
wds:Q38393045-321FA11A-B03B-4BD2-8423-B931E8023AA6
p:P478
wds:Q38393045-C6467A15-4212-4EB2-A417-416E5AD2791C
wdt:P433
21
wdt:P478
34
p:P356
wds:Q38393045-2A5A16C5-BF69-49FC-A100-E00F7CD67629
wdtn:P356
n12:JCO.2015.64.8931
wdt:P356
10.1200/JCO.2015.64.8931
p:P932
wds:Q38393045-8A567031-D3F9-41D6-A278-0FA751868172
wdt:P932
6816000